Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / Catherine Akers

Catherine Akers

Currently Regulatory Affairs Manager at Amgen, UK, Catherine Akers began her career as a clinical research associate, monitoring the conduct of clinical trials and visiting doctors responsible for trialling new drugs. “The collection of safety events for subjects is key in any clinical trial but that is only the tip of the iceberg,” says Catherine. “The continued collection of safety information once a medicine is in use ensures that benefits and risks can be carefully assessed throughout a product’s lifecycle.” As the safety of drugs continues to make newspaper headlines, Catherine believes that more measures to monitor the safety of medicines can only be a good thing. And that is where she is today; using her knowledge of drug development and current legislation to advocate for increasingly robust practices for the collection of safety events.

  • Contributions

Safety First - Sizing Up Biologics Side Effects

December 2, 2014

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

0 min read

Safety First - Sizing Up Biologics Side Effects

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.